Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

TBPH vs ANL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

TBPH Wins Head-to-Head Institutional Verdict (5–0 across 6 Pillars · 8–2 Matrix Metrics)

TBPH Overall Winner 6-Pillar Tally: TBPH 5 – 0 ANL (1 Tie) Matrix Metrics: TBPH 8 – 2 ANL

As of Nov 16, 2026, Theravance Biopharma, Inc. (TBPH) is the stronger overall head-to-head candidate over ANL (ANL) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TBPH carries a Unified Composite Score of 54.9/100 (HOLD) at $17.03 (13.4x Forward P/E, 8.9% operating margin), whereas ANL carries 48.3/100 (HOLD) at $9.97 (N/M Forward P/E, -123.5% operating margin).

  • Growth vs. Quality Trade-Off: TBPH earns the overall head-to-head edge with a stronger Unified Composite Score (54.9/100 HOLD vs. ANL 48.3/100 HOLD) and 0.48β · 2% Vol risk profile, whereas ANL leads top-line expansion (+178.1% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates.
  • Technical & Structure Timing Caution: TBPH trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.6); meanwhile ANL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About TBPH vs ANL
TBPH NASDAQ Head-to-Head Winner
Theravance Biopharma, Inc.
Pharmaceutical Preparations
$17.03
+0.0% 1D
Market Cap $884.2M
TTM Revenue $104M
Forward P/E 13.4x
Beta / 30D Vol 0.48β · 2% Vol
Unified Composite Score
54.9 / 100 HOLD
Tech 65.0 Fund 52.0 Flow 50.0 Mom 35.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 54
RSI-14: 53.6 · SMA20: $17.04 · SMA50: $16.96
ANL US Equity
ANL
Institutional Equity
$9.97
-6.03% 1D
Market Cap $677.5M
TTM Revenue $18M
Forward P/E N/M
Beta / 30D Vol 2.61β · 79% Vol
Unified Composite Score
48.3 / 100 HOLD
Tech 48.0 Fund 52.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -9.9%), weak momentum, RSI 42
RSI-14: 41.7 · SMA20: $10.30 · SMA50: $12.92

6-Pillar Scorecard Institutional Category Breakdown (TBPH 5 – 0 ANL)

Columns: Metric · TBPH · ANL
1. Valuation Multiples TBPH
Forward P/E 13.4x N/M
Trailing P/E 16.4x N/M
PEG Ratio N/M N/M
EV / Revenue 8.5x 37.5x
2. Growth & Scale TBPH
Revenue Growth (YoY) -20.9% +178.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $104M $18M
Market Cap $884.2M $677.5M
3. Profitability & Quality TBPH
Gross Margin 75.1% 100.0%
Operating Margin 8.9% -123.5%
Net Profit Margin 51.6% -124.8%
Return on Equity (ROE) 20.9% -20.2%
4. Balance Sheet & Cash Flow TBPH
Cash Generation (TTM) $11M EBITDA -$22M EBITDA
Cash Flow Margin 10.6% EBITDA Mgn -119.9% EBITDA Mgn
Net Cash / Leverage $5.58 Book/Sh · 20.9% ROE $3.34 Book/Sh · -20.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 55.0% (16th %ile) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat TBPH
OpEx & R&D Intensity 66.2% of Rev ($69M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: TBPH (8) vs ANL (2)
Institutional Metric TBPH ANL Criterion Row Edge
Market Capitalization
Scale
$884.2M $677.5M Larger Scale TBPH
Trailing P/E Ratio
Valuation
16.4x N/M Lower Multiple TBPH
Forward P/E Ratio
Valuation
13.4x N/M Lower Multiple TBPH
Revenue Growth (YoY)
Growth
-20.9% +178.1% Higher Growth ANL
Operating Margin (TTM)
Profitability
8.9% -123.5% Higher Margin TBPH
Net Profit Margin
Profitability
51.6% -124.8% Higher Margin TBPH
Return on Equity (ROE)
Capital Efficiency
20.9% -20.2% Higher ROE TBPH
52-Week Range Position
Momentum
50% ($13–$21) 56% ($1–$17) Stronger Trend ANL
Beta / 30D Volatility
Risk Regime
0.48β · 2% Vol 2.61β · 79% Vol Lower Realized Risk TBPH
Unified Institutional Score
Composite Signal
54.9 / 100 (HOLD) 48.3 / 100 (HOLD) Higher Composite TBPH
Trailing 12M Revenue (USD)
Operating Scale
$104M $18M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
75.1% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 8.5x EV/Rev N/M PEG · 37.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$11M EBITDA ($5.58 Book/Sh · 20.9% ROE) -$22M EBITDA ($3.34 Book/Sh · -20.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ANL +11.11 pp
TBPH: +0.12% · ANL: +11.23%
3M Horizon ANL +44.7 pp
TBPH: -1.39% · ANL: +43.31%
6M Horizon ANL +111.02 pp
TBPH: +14.3% · ANL: +125.32%
1Y Horizon ANL +948.18 pp
TBPH: -5.13% · ANL: +943.05%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on TBPH vs ANL. Trailing 12-month operating profitability (TBPH 8.9% vs ANL -123.5%) and valuation multiples (TBPH 13.4x vs ANL N/M Forward P/E) are benchmarked directly in Pillar 4 below.

TBPH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$104M
Gross Margin75.1%
Op. Margin8.9%
ROE / Fwd P/E20.9% · 13.4x
ANL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$18M
Gross Margin100.0%
Op. Margin-123.5%
ROE / Fwd P/E-20.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
TBPH UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 55.0%
IV Percentile 16th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact TBPH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ANL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ANL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
TBPH Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $884.2M market capitalization and 8.9% operating margin.
OpEx & R&D Reinvestment 66.2% of Rev ($69M)
90D Engineering Disclosures 0 Published
ANL Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $677.5M market capitalization and -123.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ TBPH vs ANL Key Questions & Quantitative Answers

As of Nov 16, 2026, Theravance Biopharma, Inc. (TBPH) is the stronger overall head-to-head candidate over ANL (ANL) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). TBPH carries a Unified Composite Score of 54.9/100 (HOLD) at $17.03 (13.4x Forward P/E, 8.9% operating margin), whereas ANL carries 48.3/100 (HOLD) at $9.97 (N/M Forward P/E, -123.5% operating margin). Growth vs. Quality Trade-Off: TBPH earns the overall head-to-head edge with a stronger Unified Composite Score (54.9/100 HOLD vs. ANL 48.3/100 HOLD) and 0.48β · 2% Vol risk profile, whereas ANL leads top-line expansion (+178.1% YoY revenue growth, N/M PEG, and 0 of 6 institutional pillars) for higher-beta growth mandates. Technical & Structure Timing Caution: TBPH trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 53.6); meanwhile ANL is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 41.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

TBPH leads the Growth & Scale pillar: TBPH posts -20.9% YoY revenue growth and +0.0% YoY earnings growth on $104M TTM revenue (75.1% gross margin, 8.9% operating margin), compared with ANL at +178.1% YoY revenue growth and +0.0% YoY earnings growth on $18M TTM revenue (100.0% gross margin, -123.5% operating margin). On trailing 12-month operating scale, TBPH generates $104M in USD-normalized revenue versus $18M for ANL. In operating R&D and SG&A reinvestment, TBPH deploys 66.2% of Rev ($69M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ANL.

TBPH screens cheaper on headline valuation multiples. TBPH trades at 13.4x Forward P/E, 16.4x Trailing P/E, N/M PEG, and 8.5x EV/Revenue (10.6% EBITDA margin), whereas ANL trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 37.5x EV/Revenue (-119.9% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against TBPH (20.9% ROE) versus ANL (-20.2% ROE) capital efficiency.

In options market volatility and institutional positioning, TBPH carries 55.0% implied volatility (16th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.48β · 2% Vol realized risk). By comparison, ANL carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.61β · 79% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.